CD274 and non-small cell lung carcinoma: Standard first-line treatment for patients with stage IV non-small cell lung cancer (NSCLC) without druggable molecular alterations is represented by immune checkpoint inhibitors (ICIs) alone—if programmed death ligand-1 (PD-L1) expression level is ≥50%—or—for any PD-L1 expression level—by chemo–immunotherapy combinations consisting of ICIs plus platinum-based chemotherapy [1].